On May 29, 2020 Suzhou Kintor Pharma reported that it has completed a $240 million IPO on the Hong Kong Exchange (Press release, Suzhou Kintor Pharmaceuticals, MAY 29, 2020, View Source [SID1234558695]). Kintor is focused on androgen receptor related diseases including prostate cancer, breast cancer, liver cancer and alopecia. Its pipeline includes novel small molecule drugs, biologics and combination therapies. Kintor expects its lead drug, a prostate cancer candidate known as proxalutamide, will be approved for China commercialization later this year. The IPO was more than 500 times oversubscribed, and Kintor’s shares rose slightly in initial trading

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!